ABT is trading just above its 200‑day moving average with a healthy 3.5% dividend yield and Q2 EPS beat, supporting its valuation upside. The balance sheet remains robust with a debt‑to‑equity under 0.5 and strong free cash flow.

Investor sentiment stays upbeat as the recent ‘exceeds market returns’ story drives analyst upgrades and net inflows into ABT. The broader healthcare narrative of aging demographics continues to favor long‑term demand.

Long‑term risk is muted; ABT’s diversified product portfolio and pipeline of high‑margin biologics reduce regulatory surprise risk. Demographic tailwinds and steady dividend growth bolster a multi‑year bullish view.

Technical indicators show a bullish MACD crossover and RSI hovering around 58, while daily volume is 1.4× the 30‑day average, indicating buying pressure. The stock price is consolidating near a $113 resistance, suggesting upside potential.